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Diagnosing pulmonary embolism
Not all procedures are invasive
Editor—Tony Fennerty sets his review of
the diagnosis of pulmonary embolism in the
context where pulmonary angiography is
not generally available.1 This seems a rather
backward looking approach as any modern
radiology department performing angio›
graphy should be able to perform a pulmo›
nary study. We believe that even when
pulmonary angiography is freely available, it
is not commonly requested by referring
clinicians because they are reluctant to use
an invasive procedure that they perceive as
dangerous. However, pulmonary angio›
graphy with selective angiography using
non›ionic contrast medium has a low
mortality ( < 1%) and morbidity (2›5%).2
Fennerty quotes a mortality of 0.1% from
treatment with anticoagulants, but this is
much lower than in other reported series
(1›2% mortality, 5›25% morbidity),2 which
suggests that empirical anticoagulation
should be avoided. Pulmonary angiography
should be requested more often when
isotope lung scans show an intermediate or
low probability of pulmonary embolism and
Doppler studies of the leg veins give
negative results, especially when clinical
suspicion is high.
Fennerty gives only a passing reference
to the future role of fast computed tomogra›
phy techniques, despite them having been
shown to be as reliable as angiography or
isotope scanning in detecting central pul›
monary embolism, although not in detect›
ing subsegmental acute emboli.3 The exact
role of fast computed tomography has yet to
be established, but if available it is a
non›invasive alternative to angiography
after a non›diagnostic isotope study. If the
scan is negative some centres may still
perform angiography, but a positive scan
avoids the need for angiography. Fast
computed tomography has also been cham›
pioned as a first line alternative to isotope
scanning.2 The only contraindication is a
documented adverse reaction to
intravenous iodinated contrast media.
Finally, Fennerty did not mention the
possible future role of magnetic resonance
imaging which is also evolving as a
potential non›invasive means of directly
depicting clots in the pulmonary artery. It is
a particularly attractive prospect as it avoids
iodinated contrast media and could be
combined with magnetic resonance venog›
raphy of the legs and pelvis for evaluation
of deep vein thrombosis. Currently the sen›
sitivity of magnetic resonance imaging for
segmental pulmonary embolism is inferior
to fast computed tomography.4 However,
its potential advantages necessitate its
continued development.
John A Holemans Senior registrar
John F Reidy Consultant radiologist
Department of Radiology, Guy’s and St Thomas’s
Hospital, London SE1 9RT
1 Fennerty T. The diagnosis of pulmonary embolism. BMJ
1997;314:425›9. (8 February.)
2 Goodman LR. Diagnosis of acute pulmonary embolism:
time for a new approach. Radiology 1996;199:25›7.
3 Remy›Jardin M, Remy J, Deschildre F, Artaud D, Beregi JP,
Hossein›Foucher C, et al. Diagnosis of pulmonary
embolism with spiral CT: comparison with pulmonary
angiography and scintigraphy. Radiology 1996;200:
699›706.
4 Getter WB, Hatabu H, Holland GA, Gupta KA, Henschke
CI, Palevsky HI. Pulmonary thromboembolism: recent
developments in diagnosis with CT and MR imaging.
Radiology 1995;197:561›74.
Three non›invasive techniques failed to
get a mention
Editor—In his review Tony Fennerty aimed
“to describe ways of diagnosing pulmonary
emboli without resorting to angiography”
yet failed to mention three non›invasive
techniques that are increasingly available to
clinicians in district general hospitals.1
Transthoracic cross sectional echocardi›
ography and Doppler measurements com›
monly show evidence of right heart strain
such as increased right ventricular end
diastolic diameter, leftward bulging of the
intraventricular septum in diastole, tricus›
pid regurgitation, and evidence of raised
right atrial pressure such as a low collapse
index of the inferior vena cava.2 Sometimes
emboli can be seen within the heart or main
pulmonary vessels3 although transoeso›
phageal echocardiography is more sensi›
tive.4 Where echocardiography fits in to the
diagnostic workup of patients with sus›
pected pulmonary emboli depends on how
quickly the test can be organised and how
well operators can examine right sided
structure and function.
Increasingly clinicians are requesting
echocardiograms in suspected heart failure
and also in atrial fibrillation. Pulmonary
emboli should be strongly suspected if
unexplained right ventricular enlargement
or Doppler evidence of tricuspid regurgi›
tation or pulmonary hypertension is
detected in the absence of valve disease or
left ventricular dysfunction in such patients.
Finally, spiral computed tomography
will increasingly become available. It seems
to have higher sensitivity and specificity
than transoesophageal and transthoracic
echocardiography. In a prospective series of
75 patients, 39 had evidence of pulmonary
emboli on both pulmonary angiography
and spiral computed tomography.5 The
prospective sensitivity was 91%, specificity
78%, positive predicted value 100%, and
negative predicted value 89%, comparing
favourably with pulmonary angiography.
Colin Borland Consultant physician
Hinchingbrooke Hospital, Huntingdon,
Cambridgeshire PE18 8NT
1 Fennerty T. The diagnosis of pulmonary embolism. BMJ
1997;314:425›9. (8 February.)
2 Nazarayollas P, Metz D, Chapoutot L, Chabert JP, Maillier
B, Maes D, et al. Diagnostic accuracy of echocardiography›
Doppler in acute pulmonary embolism. Int J Cardiol
1995;47:273›80.
3 Cheriox EC, Sreeram N, Eussen YF, Pieters FA, Wellens HJ.
Cross sectional Doppler echocardiography as the initial
technique for the diagnosis of acute pulmonary embolism.
Br Heart J 1994;72:52›7.
4 Patel JJ, Chandrasekaran K, Maniet AR, Ross JJ Jr, Weiss
RL, Guidotti JA. Impact of the incidental diagnosis of clini›
cally unsuspected central pulmonary artery thrombo›
embolism in treatment of critically ill patients. Chest
1994;105:986›90.
5 Remy›Jardin M, Remy J, Deschildre F, Artaud D, Beregi JP,
Hosein›Foucher C, et al. Diagnosis of pulmonary
embolism with spiral CT: comparison with pulmonary
angiography and scintigraphy. Radiology 1996;200:
699›706.
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Lung perfusion scanning is a useful
diagnostic tool
Editor—Tony Fennerty supports the use of
ventilation›perfusion scanning combined
with clinical assessment for the diagnosis of
pulmonary emboli1 but does not include
evidence from the prospective investigative
study of acute pulmonary embolism diagno›
sis.2 This study examined the role of lung
perfusion scanning and clinical assessment
in diagnosing pulmonary emboli. A positive
scan was obtained in 92% of patients with a
pulmonary embolus proved angiographi›
cally and a negative scan in 87% of patients
without a pulmonary embolus. The specifi›
city is therefore much higher than standard
ventilation›perfusion scanning (10%).3 By
adopting the recommendations of these two
studies, the need for pulmonary angio›
graphy may be reduced and the problem of
non›diagnostic ventilation›perfusion scans
avoided.
P Hawkins Registrar in general medicine
Kingston Hospital NHS Trust,
Kingston upon Thames, Surrey KT2 7QB
1 Fennerty T. The diagnosis of pulmonary embolism. BMJ
1997;314:425›9. (8 February.)
2 Miniati M, Pistolesi M, Marini C, Di Ricco G, Formichi B,
Prediletto R, et al. Value of perfusion lung scan in the diag›
nosis of pulmonary embolism: results of the prospective
investigative study of acute pulmonary embolism diagnosis
(PISA›PED). Am J Respir Crit Care Med 1996;154:1387›93.
3 PIOPED investigators. Value of the ventilation/perfusion
scan in acute pulmonary embolism. JAMA 1990;263:
2753›9.
Outcome depends on size of embolus
Editor—Although Tony Fennerty’s review
on the diagnosis of pulmonary embolism
was concise and practically helpful,1 we
would like to draw attention to an often
neglected point.
A diagnosis of pulmonary embolism is
not enough. Major and minor pulmonary
embolism must be clearly distinguished as
they are quite different clinical entities. In
the case of major pulmonary embolism,
recurrence of even a small embolus may be
immediately fatal. This danger does not exist
with minor pulmonary embolism. For
similar reasons, major and minor thrombi
must be distinguished in a diagnosis of leg
vein thrombosis. A large embolus may cause
sudden death whereas a small one does not
carry such a risk.
Any diagnostic workup in suspected pul›
monary embolism should be considered
complete only after assessing the residual
capacity of the right ventricle to cope with
additional obstruction of the lumen of the
pulmonary artery and the size of a recurrent
embolus. An unfavourable ratio of cardiopul›
monary reserve to residual thrombus volume
warrants a swift and aggressive approach. In
such patients we strongly favour placement of
a filter in the inferior vena cava, followed by
thrombolytic treatment.
Christoph Pechlaner Senior physician
Thomas Buratti House officer
Christian Wiedermann Professor
Intensive Care Unit, Department of Internal
Medicine, Innsbruck University Hospital,
A›6020 Innsbruck, Austria
1 Fennerty T. The diagnosis of pulmonary embolism. BMJ
1997;314:425›9 (8 February.)
Morbidity should be taken into account
when deciding on anticoagulant
treatment
Editor—Although Tony Fennerty provides
a good review of the diagnosis and
treatment of pulmonary embolism, we ques›
tion the reliability of the quoted mortality of
0.1% associated with anticoagulant treat›
ment for thromboembolic disease.1 This rate
is based on a study that investigated the
optimum duration of treatment for
thromboembolic disease in selected popula›
tions of hospital patients2 and cannot be
generalised to routine clinical practice. A
mortality of 0.8% for all clinical conditions
associated with oral anticoagulant treatment
was reported in a review of observational
studies.3 To quote figures only for mortality
and not morbidity for adverse events associ›
ated with oral anticoagulant treatment is
misleading. Major bleeding events may
develop in up to 12% of patients per year.4
Morbidity will obviously impinge on any
decision about anticoagulation for any clini›
cal indication. There are disagreements,
however, about the definitions of relative
severity of associated morbidity.
We agree that the incidence of major
adverse events seems to be decreasing, pos›
sibly because of improved control of the
international normalised ratio. In a ran›
domised controlled trial of the manage›
ment of oral anticoagulant treatment in
general practice we observed no fatalities in
over 300 patient years of follow up,5 which
would accord with the low figure quoted by
Fennerty.1 Given the lower target therapeu›
tic range of the international normalised
ratio in treating pulmonary embolism,
the incidence of serious adverse events
should be lower in this group of patients,
thus influencing the decision whether to
give anticoagulants to patients with this
condition.
David Fitzmaurice Senior lecturer
E T Murray Research associate
F D R Hobbs Head of department
Department of General Practice, Medical School,
University of Birmingham, Birmingham B15 2TT
1 Fennerty T. The diagnosis of pulmonary embolism. BMJ
1997;314:425›9. (8 February.)
2 Research Committees of the British Thoracic Society.
Optimum duration of anticoagulation for deep vein
thrombosis and pulmonary embolism. Lancet
1992;340:1285›8.
3 Landefeld CS, Beyth RJ. Anticoagulant related bleeding—
clinical epidemiology, prediction and prevention. Am J Med
1993;95:315›28.
4 Hamilton GM, Childers RW, Silverstern MD. Does clinic
management of anticoagulation improve the outcome of
prosthetic valve patients? Clin Res 1985;33:832A.
5 Fitzmaurice DA, Hobbs FDR, Rose P, Murray ET. A
randomised controlled trial comparing primary care oral
anticoagulant management utilising computerised deci›
sion support (DSS) and near patient testing (NPT) with
traditional management. Br J Haematol 1996;93:S30.
Intravenous antibiotic
treatment at home can provide
higher quality care
Editor—The tone of Dilip Nathwani and
Peter Davey’s article on community based
intravenous antibiotic treatment in Britain is
unnecessarily negative.1 We agree, however,
that outpatient intravenous antibiotic treat›
ment should be driven by a concern for
quality rather than as a cost saving practice.
Such therapy was developed in the United
States because clinicians wanted to maintain
quality care for patients with infections
requiring intravenous treatment in the face
of pressure from third party payers—such as
insurance companies—demanding shorter
hospital stays for given diagnoses. The
financial savings from home intravenous
treatment programmes were shown subse›
quently. Our programme in Oxford was also
developed to promote quality of care rather
than to save money. We based it not on an
existing home total parenteral nutrition
programme but on the realisation that
patients with AIDS requiring intravenous
treatment for cytomegalovirus retinitis
would have a better quality of care if such
long term treatment could be provided out›
side hospital. We expanded this programme
to treat other patients with bacterial
infections.2 Our outpatient programme for
intravenous antibiotic treatment has allowed
patients with serious infections to be given
optimal treatment without confining them
to hospital for prolonged periods. Our
patients are treated in their own homes by
district nurses supported by our community
liaison nurses and are monitored regularly
in our clinic, with 24 hour access to the ward
if problems arise.
A useful spin›off from our programme
has been a large saving in hospital bed days.
In the past five years we have treated 260
patients at home and saved 6033 bed days.
Although the value of a hospital bed day
varies in different healthcare settings, 80% of
our patients are from surgical wards, where
prolonged stays have a major impact on
waiting list times. Thus earlier discharge with
intravenous treatment at home can have
major benefits for both patients and
purchasers.
We acknowledge, however, that fund›
ing issues in the NHS are complex and
welcome the call for a nationwide NHS
strategy for purchasing outpatient intra›
venous treatment. This will allow bet›
ter planning, provide support for hospital
and community trusts to set up pro›
grammes, and, we hope, regulate the
involvement of commercial organisations
so that quality of care takes precedence over
financial considerations.
Christopher P Conlon Consultant physician
Jill Kayley Community specialist nurse
David G Lalloo Senior registrar
Anthony R Berendt Consultant physician
Infectious Diseases Unit, Nuffield Department of
Medicine, John Radcliffe Hospital, Oxford
OX3 9DU
1 Nathwani D, Davey P. Intravenous antimicrobial therapy in
the community: underused, inadequately resourced, or
irrelevant to health care in Britain? BMJ 1996;313:1541›
43. (14 December.)
2 Kayley J, Berendt AR, Snelling MJM, Moore H, Hamilton
HC, Peto TEA, et al. Safe intravenous antibiotic therapy at
home: experience of a UK based programme. J Antimicrob
Chemother 1996;37;1023›9.
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Macrocytic anaemias
Three fifths of patients with Crohn’s
disease that has not been operated on
have vitamin B12 malabsorption
Editor—In their article on macrocytic
anaemias Victor Hoffbrand and Drew
Provan mention rare inherited defects of
DNA synthesis and benign familial macro›
cytosis as causes of macrocytosis,1 yet they
fail to discuss an important cause of malab›
sorption of vitamin B12—namely, Crohn’s
disease. It has been estimated that up to
three fifths of patients with Crohn’s disease
that has not been operated on (even those
with localised ileal disease or a radiologically
normal ileum) have vitamin B12 malabsorp›
tion.2 Moreover, since an average district
general hospital serving a population of
200 000 will have about 150 patients with
Crohn’s disease, it is a fairly common cause
of B12 deficiency. The authors also state that
measuring serum gastrin concentrations
and taking gastric biopsy specimens may be
helpful in investigations of patients with
macrocytosis; in routine clinical practice
these are of little value. The authors omit to
mention IgA antibodies to gliadin. Failure to
detect these antibodies is 100% sensitive,
specific, and negatively predictive for coeliac
disease,3 a not infrequent cause of folate
deficiency and macrocytosis.
Roger Barton Reader
Department of Medicine, North Tyneside General
Hospital, North Shields NE29 8NH
1 Hoffbrand V, Provan D. ABC of clinical haematology. Mac›
rocytic anaemias. BMJ 1997;314:430›3. (8 February.)
2 Dyer NH, Dawson AM. Malnutrition and malabsorption in
Crohn’s disease with references to the effect of surgery.
Br J Surg 1973;60:134›40.
3 McMillan SA, Haughton DJ, Biggart JD, Edgar JD, Porter
KG, McNeill TA. Predictive value for coeliac disease of
antibodies to gliadin, endomysium, and jejunum in
patients attending for jejunal biopsy. BMJ 1991;
303:1163›5.
Authors’ reply
Editor—We agree with Roger Barton that
tests for serum antibodies to gliadin and
endomysium are extremely useful screening
tests for enteropathy induced by gluten. We
are less certain of the importance of Crohn’s
disease uncomplicated by an ileal resection
or an intestinal stagnant loop as a frequent
cause of megaloblastic anaemia due to
vitamin B12 deficiency.
Our article dealt with macrocytic anae›
mias, but because of limitations on space we
did not detail causes of vitamin B12
deficiency, which are only rarely of sufficient
severity to lead to megaloblastic anaemia. A
large number of conditions exist in which
vitamin B12 malabsorption occurs and
serum vitamin B12 concentrations may be
subnormal, but these conditions rarely
present as macrocytic anaemias due to vita›
min B12 deficiency. Indeed, enteropathy
induced by gluten would be one such exam›
ple. Our studies of Crohn’s disease found
that folate deficiency occurred commonly in
patients with active disease but that mega›
loblastic anaemia due to B12 deficiency was
largely associated with ileal resection or
intestinal stagnant loop (both of which were
listed in our article as causes of severe
vitamin B12 deficiency).
1 This experience is
also reported by others.2
A V Hoffbrand Professor of haematology
Royal Free Hospital, London NW3 2QG
D Provan Haematologist
Southampton University Hospitals NHS Trust,
Southampton SO9 4XY
1 Hoffbrand AV, Stewart JS, Booth CC, Mollin DL. Folate
deficiency in Crohn’s disease: incidence, pathogenesis, and
treatment. BMJ 1968;ii:71›5.
2 Chanarin I. The megaloblastic anaemias. 2nd ed. London:
Blackwell Scientific, 1979:416›7.
Pancreatic angiography is still
valuable preoperatively in
insulinoma
Editor—The Lesson of the Week by
R Perros and colleagues underlines the
importance of establishing a firm pre›
operative—indeed, a pre›imaging—clinical
diagnosis in cases of suspected insulinoma.1
Since the equivocal findings on pancreatic
imaging were a factor in this case, we think it
important to emphasise that pancreatic
angiography is still a valuable preoperative
investigation in insulinoma, even if intra›
operative ultrasonography is planned. We
would make two points not mentioned in
the article. Firstly, coeliac angiography alone
(if this is really what was performed) would
not generally be considered to be adequate
in angiographic exploration of the pancreas
in such cases. Selective gastroduodenal,
splenic, and dorsal pancreatic arteriograms
are required to maximise the chances of
detecting an insulinoma and to reduce the
incidence of false positive findings.2
Secondly, the discussion makes no mention
of hepatic venous sampling after selective
pancreatic arterial stimulation. This tech›
nique can be performed as a simple
extension to the angiography described and
is reported as being comparable in sensi›
tivity to portal venous sampling in the detec›
tion of insulinoma but with none of its
attendant risks.3 We have avoided portal
venous sampling by using hepatic venous
sampling after selective pancreatic arterial
stimulation (fig 1) and believe that this tech›
nique should be used whenever invasive
localisation with pancreatic angiography is
being performed. In the case in question its
use would almost certainly have raised
doubts about the clinical diagnosis before
surgery was undertaken.
D M Nichols Consultant radiologist
J R C Logie Consultant surgeon
P Zentler›Munro Consultant physician
Department of Radiology, Raigmore Hospital,
Inverness IV2 3UJ
1 Perros P, Henderson AK, Carter DC, Toft AD. Are spon›
taneous hypoglycaemia, raised plasma insulin and
C peptide concentrations, and abnormal pancreatic
images enough to diagnose insulinoma? BMJ 1997;314:
496›7. (15 February.)
2 Miller DJ. Endocrine angiography and venous sampling.
Radiol Clin N Am 1993;31:1051›67.
3 Doppman JL, Miller DJ, Chang R, et al. Insulinomas: locali›
sation with selective intra›arterial injection of calcium.
Radiology 1991;178:237›41.
Public is concerned about gene
testing
Editor—The decision of the Association of
British Insurers that the results of genetic
tests should be taken into account when new
applications for insurance cover over
£100 000 are being considered has created a
dilemma for the public.1 As has been
suggested, individuals may opt not to be
tested or to choose private testing rather
than the NHS. This situation potentially
compromises the health of those who are at
risk of heritable disease and creates novel
uncertainty for those who are not.
In medical research, ethical issues also
remain to be resolved. Large scale auto›
mated genetic testing is now possible, and
the funds available for genetic research will
generate considerable activity in the near
future. Key questions relate to informed
consent and the transfer of DNA samples by
researchers to third parties.
We commissioned an opinion poll to
examine public attitudes both to insurers’
use of genetic tests and to genetic testing in
medical research. NOP Research Group
carried out a telephone omnibus survey of a
nationally representative sample of 1000
adults on 21›23 February this year. Two
hundred and eighty respondents said they
would not take a genetic test now that they
are required to disclose the results to their
insurance company. A larger proportion,
358, would object if a tissue sample which
they had given anonymously was used in
genetic research without their knowledge or
consent. Of greater concern, 699 respond›
ents indicated that they would object if their
anonymised tissue was sold to a pharmaceu›
tical company without their knowledge or
consent.
The results of our poll suggest that we
may regret the relative lack of concern over
the issue of informed consent in Britain.2
The Convention on Human Rights and Bio›
medicine adopted by the Council of Europe
last year indicates that samples may be


















Fig 1 Arterial stimulation›venous sampling in
insulinoma of pancreatic tail, showing changing
serum insulin concentrations in hepatic vein
catheters after calcium injection into each of splenic
(_), gastroduodenal (s), and inferior
pancreaticoduodenal arteries (×)
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those for which they were collected, “in con›
formity with appropriate consent proce›
dures.” Informed commentators take the
view that a court would probably regard
blanket consent as inappropriate. At present
the public is broadly happy to donate
samples and to assist medical research in
other ways. This willingness to cooperate
should be safeguarded with guidelines that
provide a clear ethical framework for
research in human genetics.
E J Brunner Chair, management committee
J Sheppard Consultant
J Ravetz Member, management committee
Genetics Forum, London EC2A 2BH
1 Kmietowicz Z. Health put at risk by insurers’ demands for
gene test results. BMJ 1997;314:625. (1 March.)
2 American Society of Human Genetics. Statement on
informed consent for genetic research. Am J Hum Genet
1996;59:471›4.
Leukaemia near La Hague
nuclear plant
Bias could have been introduced into
study
Editor—Dominique Pobel and Jean›
François Viel found an association between
going to the beach more than once a month
and leukaemia risk, with an odds ratio of
2.87.1 Eighty two out of 192 controls were
engaged in this activity. If this association
were causal, we could expect, roughly, a
twofold increase in the incidence of
childhood leukaemia in the Nord›Cotentin.
Previously, however, the authors had
observed an incidence similar to the
expected figures (standardised incidence
ratio of 1.1),2 which suggests that a bias
could have been introduced in the study
design. This issue should be systematically
and carefully investigated.
A recall bias could not be ruled out.
A selection bias may easily occur since the
source population used for identifying
controls is ill defined. The control group
was identified by the general practitioners
who had provided care to the case children.
Underlying this design are the tacit
assumptions that all the cases were followed
by a general practitioner at their time of
diagnosis, that those general practitioners
are still in practice, and that all the children
of the source population were followed by
a general practitioner who is still practising.
Are these assumptions justified by any
evidence? Was the catchment area for
these general practitioners identical in
1994›5 (recruitment of controls’ parents)
and between 1978 and 1993 (recruitment
of cases)?
Although the differences are not statisti›
cally significant, fathers of cases were ranked
in higher social categories than fathers of
controls. Some additional criteria would also
be useful for comparing cases and controls.
For instance, did the controls live farther
from the beaches than cases, conditionally
on matching? Did they live in similarly sized
communities?
To what extent are the variables of inter›
est correlated—mothers’ seaside activity dur›
ing pregnancy, children’s seaside activity,
consumption of local shellfish, living in a
granite house? To what extent are these vari›
ables correlated with the distance between
the subjects’ homes and the beach or with
social category or any other characteristic?
Numbers allow adjustments, at least when
dichotomous variables are used; could the
authors show such multivariate analysis?
The authors say they found an excess of
childhood leukaemia in the electoral ward
containing the reprocessing plant; in a
previous paper2 they reported four cases in
this ward from 1978 to 1992 versus 1.4
expected. The four case children played on
the beach at least once a month; what about
the controls in this ward?
Jacqueline Clavel Researcher
Denis HØmon Head
Department of Epidemiological and Statistical
Research on Environment and Health, INSERM,
Unit 170, 16 Avenue Paul Vaillant›Couturier, 94807
Villejuif Cedex, France
1 Pobel D, Viel J›F. Case›control study of leukaemia among
young people near La Hague nuclear reprocessing plant:
the environmental hypothesis revisited. BMJ 1996;
314:101›6. (11 January.)
2 Viel J›F, Pobel D, CarrØ A. Incidence of leukaemia around
La Hague nuclear waste reprocessing plant: a sensitivity
analysis. Stat Med 1995;14:2459›72.
Study design is questionable
Editor—We were surprised by the strength
of Dominique Pobel and Jean›François
Viel’s conclusion that “there is some
convincing evidence in childhood leukae›
mia of a causal role for environmental radia›
tion exposure from recreational activities on
beaches.”1
The study region was restricted to a cir›
cle (diameter 35 km) around the La Hague
reprocessing plant. Since their original aim
was to investigate the apparent increase in
incidence of leukaemia in the vicinity of the
plant,2 the design of the study was not ideal
for examining recreational activities and
food consumption. Cases and controls were
tightly matched on geographical region at
diagnosis and loosely matched for age. The
exposure of interest, parents’ recall of their
own and their children’s dietary and recrea›
tional behaviour, may have occurred 30
years or more in the past. Further, there was
little information about the control families
who refused to participate.
Of the 27 patients ascertained during
the 16 year study period, six were young
adults (not children) and two had chronic
myeloid leukaemia. Given the wide age
range, the different diagnostic groups, the
small size of the sample, and the multiple
tests performed (173 exposure items with
one or more methods of testing), we believe
that these findings warrant a far more
cautious interpretation. Further, the findings
rely heavily on tests for trend, which seem
predominantly to have been applied even
when associations were not statistically
significant. The trend statistic is not a
traditional epidemiological tool and
requires justification under these circum›
stances. As an example, the figure gives 95%
confidence intervals of the relative risk
estimates for offspring’s recreational activity
on local beaches (from Pobel and Viel’s
table 4). The lower limits are all below 1, and
other dose›response relations, other than a
positive linear trend, could fit within the
range of each estimate.
Although the possibility that novel path›
ways of the type proposed should not be
discounted,3 we are not persuaded that
Pobel and Viel’s study provides convincing
evidence one way or the other.
Graham Law Research fellow
Eve Roman Senior lecturer
Leukaemia Research Fund Centre for Clinical
Epidemiology, University of Leeds, Leeds LS2 9GG
1 Pobel D, Viel J›F. Case›control study of leukaemia among
young people near La Hague nuclear reprocessing plant:
the environmental hypothesis revisited. BMJ 1997;
314:101›6. (11 January.)
2 Viel J›F, Pobel D. Incidence of leukaemia in young people
around the La Hague nuclear waste reprocessing plant: a
sensitivity analysis. Stat Med 1995:14:2459›72.
3 Urquhart JD, Black RJ, Muirhead MJ, Sharp L, Maxwell M,
Eden OB, et al. Case›control study of leukaemia and non›
Hodgkin’s lymphoma in children in Caithness near the
Dounreay nuclear installation. BMJ 1991:302:687›92.
Scientific context is needed
Editor—Dominique Pobel and Jean›
François Viel found associations between
childhood leukaemia and the use of beaches
around the La Hague nuclear fuel reproc›
essing plant in Normandy by pregnant
women and children and the consumption
of local seafood by children, which they
relate to possible exposure to environmental
radioactivity.1 They do not, however, pay suf›
ficient attention to the scientific context of
their results.
In an equivalent case›control study con›
ducted around Sellafield, west Cumbria,
Gardner et al found no associations between
childhood leukaemia and these lifestyle fac›
tors when using the appropriate “local” con›
trol group, and they drew attention to the
“low quality” of data based entirely on ques›
tionnaires because of the real (and unquan›
tifiable) possibility of recall bias.2 This must
be particularly so for births over a period of



























Frequency of beach visits
Fig 1 Risk of leukaemia in association with
recreational activity on local beaches
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Further, Pobel and Viel do not refer to
the vast amount of relevant research carried
out on environmental radioactivity over the
past decade, which has been summarised
recently by reports from the National
Radiological Protection Board and the
Committee on Medical Aspects of Radiation
in the Environment (COMARE).3 COMARE
concluded that radiation doses due to
discharges are “far too small” to account for
the excess of childhood leukaemia near Sell›
afield. Although Pobel and Viel note the
results of the case›control study conducted
around Dounreay in Caithness, in which an
association between leukaemia and the use
of local beaches by children (again based
solely on questionnaire data) was also found,
they do not refer to the subsequent detailed
investigation in the Dounreay area by
Watson and Sumner, who carried out a
sophisticated programme of measurements
of radioactivity in children who had been
diagnosed with leukaemia and in unaffected
children.4 They found no indication of un›
usual levels of radioactivity.
Set against the weak and inconsistent
epidemiological evidence for an effect of
environmental radioactivity on childhood
leukaemia in the vicinity of reprocessing
plants is the evidence for the influence of
unusual population mixing in these areas, of
which Pobel and Viel make no mention.
Kinlen has produced compelling evidence
from a series of studies for the impact on
childhood leukaemia of the mixing of urban
and rural populations.5 Indeed, given this
evidence, it would be surprising if the large
construction projects at La Hague and at
nearby sites had not raised the risk of child›
hood leukaemia in this area. The potentially
important effect of population mixing on
the communities surrounding La Hague
should at least have been noted.
Richard Wakeford Principal research scientist
British Nuclear Fuels, Risley, Warrington, Cheshire
WA3 6AS
1 Pobel D, Viel J›F. Case›control study of leukaemia among
young people near La Hague nuclear reprocessing plant:
the environmental hypothesis revisited. BMJ 1997;
314:101›6. (11 January.)
2 Gardner MJ, Snee MP, Hall AJ, Powell CA, Downes S,
Terrell JD. Results of case›control study of leukaemia and
lymphoma among young people near Sellafield nuclear
plant in West Cumbria. BMJ 1990;300:423›9.
3 Committee on Medical Aspects of Radiation in the
Environment (COMARE). Fourth report. The incidence of
cancer and leukaemia in young people in the vicinity of the Sell›
afield site, west Cumbria: further studies and an update of the
situation since the publication of the report of the Black Advisory
Group in 1984. Wetherby: Department of Health, 1996.
4 Watson WS, Sumner DJ. The measurement of radioactivity
in people living near the Dounreay nuclear establishment,
Caithness, Scotland. Int J Radiat Biol 1996;70:117›30.
5 Kinlen LJ. Epidemiological evidence for an infective basis
in childhood leukaemia. Br J Cancer 1995;71:1›5.
Case›control studies have been done in
Britain
Editor—As authors of a case›control study
of leukaemia in children living near nuclear
establishments in southern England, we are
interested in the case›control study of
leukaemia in young people near the La
Hague nuclear reprocessing plant.1 Our
study found no links with environmental
factors, despite larger numbers and a
comprehensive structured questionnaire.2 In
our original report of leukaemia in children
age 0›14 years diagnosed between 1972›
1985, the excess was most marked in
children aged 0›4 years living within 10 km
of the nuclear establishments at Aldermas›
ton and Burghfield,3 where a doubling in
risk was found.
Anxieties have been raised again in the
local community by media reports of
uranium contamination at the former
Greenham Common airbase and a
newspaper report of increased mortality
from childhood leukaemia at Newbury. In
view of this we have collated our clinic
figures for a further 11 years, giving data for
the whole of west Berkshire for 25 years
(table 1). The findings for the two periods
are similar, although data for 1986›96 may
be incomplete since some children resident
in the study area may not have been treated
at our clinic. There was no increase in the
relapse rate or death rate in those with acute
lymphoblastic leukaemia, who have been
entered into Medical Research Council
trials since 1972 (S Richards, personal
communication).
Further studies are planned with the
Childhood Cancer Research Group, the
Oxford Cancer Intelligence Unit, the New›
bury Leukaemia Study Group, and the
Berkshire Health Authority. We will assess
whether the additional and original cases
are geographically related to Greenham or
the Atomic Weapons Establishments plants
and extend the age range studied to 25. It
would be interesting to re›examine the inci›
dence of childhood cancer in the same areas
of west Berkshire, as a previous report
suggests that the incidence of solid tumours
is also raised.4 We hope that some reason or
environmental cause can then be postulated.
Carol Barton Consultant haematologist
Hilary Ryder Malcolm Sargent social worker
Royal Berkshire Hospital, Reading, Berkshire,
RG1 5AN
1 Pobel D, Viel J›F. Case›control study of leukaemia among
young people near the La Hague nuclear reprocessing
plant: the environmental hypothesis revisited. BMJ 1997;
314:101›106. (11 January.)
2 Roman E, Watson A, Beral V, Buckle S, Bull D, Bauer K, et
al. Case control study of leukaemia and non›Hodgkins
lymphoma among children age 0›4 living in W. Berks. and
N. Hants. Health Districts. BMJ 1993;306:615›621.
3 Roman E, Beral V, Carpenter L, Watson A, Barton C,
Ryder H, et al. Childhood leukaemia in the West Berkshire
and Basingstoke and North Hampshire District Health
Authorities in relation to nuclear establishments in the
vicinity. BMJ 1987;274:597›602.
4 Committee on Medical Aspects of Radiation in the
Environment. Third report. Report on the incidence of
childhood cancer in the West Berkshire and North Hampshire
area, in which are situated the Atomic Weapons Research
Establishment, Aldermaston, and the Royal Ordnance Factory,
Burghfield. (Chairman Professor M Bobrow.) London: HMSO,
1989.
Deformed insects have been found near
nuclear plants
Editor—Dominique Pobel and Jean›
François Viel’s article touches on people’s
worries about radiation.1 Before starting to
study deformations induced by radiation I
worked as a scientific illustrator for the Uni›
versity of Zurich for 25 years, mainly for
geneticists and taxonomists, and I had
painted leafbugs (Heteroptera) for 15 years
in my spare time. Painting mutant fruitflies
(Drosophilidae) and normal fruitflies of
different families was my main task at the
institute and gave me an idea of how nature
could look if we go on polluting our
environment as we do.
After Chernobyl, I went to contaminated
places in Sweden and the Ticino area of
Switzerland to look at leafbugs. In summer
1987 I started to collect leafbugs in the areas
of Osterfarnebo and Gavle in Sweden and
Mendrisiotto in Switzerland, and brought
back two pairs of Drosophila melanogaster,
which I bred in my kitchen as was done in
the laboratory. From the first generation I
found many deformations of the eyes,
antennae, vibrissae, bristles, segments of the
abdomen, and wings. The leafbugs were
mostly deformed on their antennae, wings,
and legs. In Sweden I also found plants with
leaf colour changed from green to dark red
or changed colour of flowers; I found heavily
deformed leaves in Sweden and in the
Ticino.
In 1988 I started to collect leafbugs in
the main wind directions of the nuclear
power plants Gosgen and Leibstadt in Swit›
zerland, where I found the most worrying
changes (fig 1). I continued these studies in
Sellafield in 1989, Chernobyl in 1990, Three
Mile Island in 1992, and Krummel in 1995.
Since 1993 I have been studying
leafbugs in the canton of Aargau, Switzer›
land, which contains four nuclear power
plants and one research plant. I collect 65
leafbugs at each of 40 points. The insects
with the greatest deformities are found close
Table 1 Incidence of childhood leukaemia in west Berkshire 1972›96 by age and time period (expected
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*Excludes one child residing and treated in the study area who was diagnosed while on holiday elsewhere in England; when
the child is included the figures are 1.6 (1.1 to 2.3) and 1.7 (1.3 to 2.1) respectively for 1986›96 and 1972›96.
†Excludes two children: one who was not registered in the national scheme, and one whose initial diagnosis of leukaemia was
revised to non›Hodgkin’s lymphoma.
Letters
1554 BMJ VOLUME 314 24 MAY 1997
(5›10 km) to the plants, to the east,
southeast, and south; less severe, but
frequent, deformations are found southwest
of the plants.
In my work, I document not just the
quantity but also, by painting the deformed
leafbugs, the quality of the deformations.
When I have published my work in Switzer›
land, suggesting that there is a connection
between low level radiation from the nuclear
plants and the malformations, I have been
heavily attacked by scientists.
Cornelia Hesse›Honegger Scientific illustrator
Feldeggstrasse 21, CH›8008 Zurich, Switzerland
1 Pobel D, Viel J›F. Case›control study of leukaemia among
young people near La Hague nuclear reprocessing plant:
the environmental hypothesis revisited. BMJ 1997;
314:101›6. (11 January.)
Author’s reply
Editor—Jacqueline Clavel and Denis
HØmon seem concerned that, as the control
selection process relied on general practi›
tioners, there may have been a selection bias.
However, the control children were not ill
defined, since any parents of a child fulfilling
the matching criteria, and not children con›
sulting general practitioners, were asked to
join the study. The assumptions about
general practitioners’ practices are broadly
true in this rural area, but I recognise that
the stability of catchment areas across time
cannot be checked.
Although I have already addressed this
issue,1 they still want to know if the controls
live farther from the beaches than cases, but
this time conditionally on matching. The
results remain non›significant for the closest
coast, Vauville beach, and Urville›
Nacqueville beach (P = 0.43, 0.18, and 0.76,
respectively).
Among the four significant exposures
(use of local beaches by mothers, use of
beaches by children, consumption of local
fish by children, and children living in a gra›
nitic area), only the first two were signifi›
cantly correlated (P < 0.0001); no other
pairwise test yielded significant results
among controls (0.65 > P > 0.24). In the
electoral ward containing the reprocessing
plant, all of the four case children played on
the beach at least once a month, whereas
only 14 of the 33 controls did so (P = 0.05).
The independent role played by each of the
three children’s factors is confirmed by a
multivariate analysis despite a lack of statisti›
cal power on this small dataset (odds ratios:
fish consumption = 7.01, P = 0.05; beach
activity = 2.56, P = 0.09; granitic area = 4.15,
P = 0.05).
Graham Law and Eve Roman have com›
mented on the parents’ recall. Exposures may
have occurred far in the past and, as in almost
every study, some degree of misclassification
is inevitable. But the reliability of maternally
reported information, in a similar context, has
recently been shown to be affected little by
time from birth or determination of case›
control status.2 Moreover, media coverage on
leukaemia clusters around nuclear facilities
had never occurred in France before, nor had
a possibility of marine contamination been
put forward. Hence, misclassification would
be random with regard to case status and
should tend to obscure rather than create
associations.
Richard Wakeford sets his hopes on the
viral hypothesis. Even if a candidate virus is
still to be found, and if the British evidence is
not so compelling, this is at variance with
some French findings.3
I hope this additional information will
convince the authors that selection or recall
biases are unlikely, and that new methods
for identifying the environmental pathways
are warranted.
Jean›François Viel Professor of biostatistics and
epidemiology
Department of Public Health, Faculty of Medicine,
25030 Besançon, France
1 Viel J›F. Criticism of study of childhood leukaemia near
French nuclear reprocessing plant is unfounded. BMJ
1997;314:301.
2 Olson JE, Shu XO, Ross JA, Pendergrass T, Robison LL.
Medical record validation of maternally reported birth
characteristics and pregnancy related events: a report from
the Children’s Cancer Group. Am J Epidemiol 1997;145:58›
67.
3 Laplanche A, de Vathaire F. Leukaemia mortality in
French communes (administrative units) with a large and
rapid population increase. Br J Cancer 1994;69:110›3.
Advertisements for donepezil
(Aricept) in the BMJ
Advertisement suggests an unrealistic
improvement in mental status
Editor—I wish to express my anger and con›
cern that advertising space on the wrapper
around the clinical research edition of the
BMJ (issues of 3 and 10 May) was sold to pro›
mote donepezil hydrochloride (Aricept). This
is the first time that I have been aware of a
promotion of this nature, and I find this form
of advertising disturbing. While I appreciate
that the BMJ generates necessary income
from pharmaceutical companies and I can
deal with advertisements within the journal, I
find that to be faced by a paper strip on top of
the BMJ that has to be forcefully removed
before one can even read the contents page is
irritating and intrusive. No doubt because of
this, it is a successful marketing ploy and gen›
erates enormous amounts of income. As a
general policy, however, I hope that the jour›
nal will reconsider accepting this type of
advertisement, as I am sure I am not alone in
finding it offensive.
The BMJ has taken great strides in
supporting a critical and rational use of the
evidence base in medicine. What policy is
adopted in scrutinising the content of adver›
tisements placed in the BMJ ? The promo›
tion for donepezil—“Mum has Alzheimer’s
but she knew I was calling today” and the
related photographs—implies that in
patients with Alzheimer’s disease treatment
with the drug will improve function enough
to have a measurable impact on the carer’s
mood. As far I am aware there has been one
published randomised controlled trial of the
use of donepezil in Alzheimer’s disease, and
this showed no improvement in the quality
of life of carers.1 The advertisement suggests
an unrealistic improvement in the mental
status of patients.
Selena Gray Senior lecturer in public health medicine
University of Bristol, Bristol BS8 1TH
1 Rogers SL, Friedhoff LT and Donepezil Study Group.
The efficacy and safety of donepezil in patients with
Alzheimer’s disease: results of the US multicentre
randomised, double›blind, placebo›controlled trial.
Dementia 1996;7:293›303.
Local committee has declined to approve
NHS hospital prescription of donepezil
Editor—The fact that the BMJ of 10 May
carried an external binder, a full page adver›
tisement, and an insert summary for the
product characteristics of donepezil hydro›
chloride (Aricept), the recently launched
drug for Alzheimer’s disease, spoilt my
weekend.
I am a singlehanded psychogeriatrician
serving a population of 30 000 patients aged
over 65 years, spread over 2124 km2. I am
not alone among my colleagues in having
just about kept my head above water (with a
catchment population over twice that rec›
ommended by the old age section of the
Royal College of Psychiatrists) until now,
when the rising tide has finally broken the
defences. My referral rate for the assessment
of patients aged over 65 with presumed
organic mental disorder has soared, my
re›referral rate is soaring too, and so are
queries about donepezil from patients, rela›
tives, carers, general practitioners, commu›
nity psychiatric nurses, and other consult›
ants. My waiting time for first outpatient
appointments has increased from seven to
10 weeks and will soon break the standard in
my local patient’s charter (12 weeks).
My local health authority has just
refused my trust the final £20 000 needed to
fund a sorely needed additional consultant
in adult psychiatry. Thus I cannot very well
hand all elderly patients with functional
problems over to my colleagues in order to
Fig 1 Leafbugs found in the grounds of the Paul
Scherrer Institute, Villigen, Switzerland, an institute
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concentrate on patients with organic prob›
lems. My local drugs and therapeutics
committee has just followed the health
authority’s directive and declined to approve
the NHS hospital prescription of donepezil.
None of the local fundholding general prac›
titioners to whom I have spoken, who have
patients who could benefit from this drug,
are prepared to pay the estimated £1000 a
year for it.
I shall be writing three private prescrip›
tions for donepezil this week, thinking of the
80 or so patients in Herefordshire who
might benefit from the drug and all those
patients and carers who would be better
served by at least two of me.
Nicholas Wagner Consultant in mental health for the
elderly
Stonebow Unit, County Hospital, Hereford
HR1 2ER
*** The BMJ carries advertising to provide
financial support to the journal and
information to readers. Advertising must be
immediately recognisable as such, and we
never sell advertising linked to editorial
material (unlike many medical newspapers).
All advertisements are approved by the
editorial team, but as European and British
legislation governs pharmaceutical advertis›
ing we rarely reject advertisements on the
grounds of unsubstantiated or misleading
claims. We sometimes reject advertising
because we think that readers will find it
offensive, but generally our policy is liberal.
Readers are well able to tell the difference
between advertising and editorial material.
Donepezil hydrochloride has received a
product licence, and the manufacturer natu›
rally wants to promote it.
We monitor all complaints from readers,
and this is the first we have received about
advertising wrappers despite their having
been used intermittently for two years. The




Medicine Institute of the UK
Editor—Mark E Batt and Donald A D
Macleod’s editorial about sports medicine
outlined the needs of and approach
required for the development of sport and
exercise medicine in Britain.1 I was disap›
pointed, though, that there was no mention
or recognition of the role and work of the
National Sports Medicine Institute of the
United Kingdom. This is especially so as
both authors are current members of the
management committee. I appreciate that
many people and organisations have
laboured towards the recognition of sport
and exercise medicine, but the role of the
institute and especially its past chairman,
Ossie Wheatley, who chaired the working
party, deserves some mention.
The institute was set up to be an umbrella
organisation that would facilitate the develop›
ment of the medical care of sports people at
all levels. We have consistently advocated
regulated training and examination under
the auspices of the royal colleges with a view
to the establishment of sport and exercise
medicine as a recognised specialty. Sport
needs a structured delivery of care, which
cannot exist without such control and recog›
nition. We look forward to the formation of
the board of sport and exercise medicine by
the Academy of Royal Colleges as it is only
through the royal colleges that appropriate
development can be achieved. The role of the
National Sports Medicine Institute of the
United Kingdom is still evolving. It is up to
those on the management committee to
ensure that the institute serves both sport and
the profession and becomes the single
respected voice for its member organisations,
which include the royal colleges and the Brit›
ish Association of Sport and Medicine.
Neil Townshend Chairman
National Sports Medicine Institute of the UK,
Broadway, Worcestershire WR12 7AJ
1 Batt ME, Macleod DAD. The coming of age of sports
medicine. BMJ 1997;314:621. (1 March.)
Cancellation of debt of poorest
people would be worthy
memorial to millennium
Editor—Andrew Haines and Richard
Smith rightly argue that the increasing
disparity in wealth, between and within
countries, is having such a profound effect
on health that doctors must cooperate with
others to analyse the “pathology” of poverty
and lobby for change.1 Medical Action for
Global Security, the British affiliate of Inter›
national Physicians for the Prevention of
Nuclear War, is doing just that. By linking
with health professionals globally and by
working with economists, we are examining
why health gains are being eroded in parts
of the world.
Of the many obstacles to reducing
poverty, debt repayment is among the most
formidable. By the end of the decade more
than half of sub›Saharan Africa’s
population—300 million people—will be
living in poverty; sub›Saharan Africa is the
only region of the world where malnutrition
is rising. Nevertheless, the region struggles to
service a debt that has reached two and a half
times its annual export earnings.2 Four times
more is spent on servicing debt than on
health. Far from being the caricatured “basket
cases,” many African countries had successful
primary health care in the 1970s and impres›
sive achievements in literacy, child mortality,
and life expectancy.3 But throughout the
1980s these achievements were eroded as
money was diverted from social spending to
debt servicing. By 1990 many African
countries were spending less per capita on
health than they had done in 1980.
It is ironic that the World Bank, which is
the main source of funding for health (total
annual health lending roughly $3bn4), is
also the organisation responsible for some
of this deterioration. With the shift in
emphasis from state provision to privatisa›
tion and “cost recovery” poor people have
been asked to pay for health and education,
which they cannot afford. The bank’s
policies are so driven by monetarist ideology
that the living standards of millions take sec›
ond place to chasing some economic
nirvana. Is it right that a bank should dictate
global health strategy to such an extent?
I suggest that health professionals could
adopt the idea of a jubilee for 2000: a one off
cancellation of the unpayable debt of the
poorest people, in countries where health as
a basic right has been revoked. Surely it
would be a worthier memorial to the millen›
nium than the construction of a Ferris wheel
in London.
Dorothy Logie General practitioner
Medical Action for Global Security, London
N19 4DJ
1 Haines A, Smith R. Working together to reduce poverty’s
damage. BMJ 1997;314:529›30. (22 February.)
2 Pettifor A. A fresh start for Africa. London: Christian Aid,
1996. (Debt Crisis Network working paper.)
3 United Nations Development Programme. The human
development report 1991. New York: Oxford University
Press, 1991.
4 The World Bank, listening and learning [editorial]. Lancet
1996;347:411.
Nurses are right not to take on
responsibilities for which they
have not been properly
prepared
Editor—I write in response to the letter
from J C Hughes about the need for nurses
to accept more responsibility and for
doctors to receive better training in the care
of terminally ill patients.1 I agree with much
that Hughes says, but it is important to put
the record straight about the “rules” of the
United Kingdom Central Council for Nurs›
ing, Midwifery and Health Visiting.
Hughes states that “nurses do not have
to do anything they do not feel competent to
do.” This is not, as Hughes reports, an edict
from the central council to the effect that
individuals should renege on their proper
and appropriate professional responsibili›
ties. Indeed, it is just the opposite. The intent,
as would be expected with any responsible
professional organisation, is to ensure that
nurses do not take on roles and responsibili›
ties for which they have not been properly
prepared and that might be to the detriment
of patients’ and clients’ safety. Surely all
health care professionals would agree with
this position.
All those on our register (about
650 000) have a personal professional
accountability for their actions and can
therefore be called to account for all that
they undertake. It would be irresponsible in
the extreme were they to take on additional
activity merely because they had been told
or asked to do so by others.
Margaret Wallace Director of standards promotion
United Kingdom Central Council for Nursing,
Midwifery and Health Visiting, London W1N 4JT
1 Hughes JC. Doctors, nurses, and terminal care. BMJ
1997;314:306. (25 January.)
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